Are Second-Generation Antipsychotics Useful in Tardive Dystonia?

Abstract:

OBJECTIVE:To review the current evidence on the effectiveness of second-generation antipsychotics (SGAs) in the treatment of tardive dystonia (TDt) and give recommendations for treatment. METHODS:Medline/PubMed/Psyclit/Embase database searches were conducted in January 2015, and a manual review of references within the retrieved articles was done. All articles in English and those that had English abstracts and dealt with treatment of TDt were included. RESULTS:Our search and review yielded a total of 88 reports (none of them a controlled trial) involving 145 patients treated with one of the 5 SGAs. Clozapine has the maximum number of published reports (52 reports involving 90 subjects, whereas there were 36 reports involving 55 subjects treated with other SGAs, including olanzapine, risperidone, quetiapine, aripiprazole, and perospirone). CONCLUSIONS:The available evidence points to the effectiveness of clozapine as monotherapy and in combination with clonazepam for the treatment of TDt. When clozapine is not an option, olanzapine and quetiapine are reasonable alternatives. Given the lack of controlled trials, future focus should be on conducting randomized, placebo-controlled, multicenter, collaborative controlled clinical trials of several years' duration.

journal_name

Clin Neuropharmacol

authors

Pinninti NR,Faden J,Adityanjee A

doi

10.1097/WNF.0000000000000106

subject

Has Abstract

pub_date

2015-09-01 00:00:00

pages

183-97

issue

5

eissn

0362-5664

issn

1537-162X

journal_volume

38

pub_type

杂志文章,评审
  • The syndrome of irreversible lithium-effectuated neurotoxicity.

    abstract:OBJECTIVES:Persistent sequelae of lithium intoxication gained clinical attention in the 1980s and were named Syndrome of Irreversible Lithium-Effectuated Neurotoxicity (SILENT). The authors review the published cases of SILENT reported in the literature and discuss various clinical manifestations. METHODS:The authors'...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/01.wnf.0000150871.52253.b7

    authors: Adityanjee,Munshi KR,Thampy A

    更新日期:2005-01-01 00:00:00

  • Central action of cinnarizine and flunarizine: a saccadic eye movement study.

    abstract::The mechanism of action of flunarizine (FZ) and cinnarizine (CZ) on the CNS is not fully understood. Computer analysis of saccadic eye movements (SEM) provides a sensitive and objective method for evaluating drug effect on the function of specific brain structures. This study aimed to assess the effect of a single ora...

    journal_title:Clinical neuropharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/00002826-199410000-00003

    authors: Casucci G,Di Costanzo A,Riva R,Albani F,Bonavita V,Tedeschi G

    更新日期:1994-10-01 00:00:00

  • Brain monoamine output alterations after a single venlafaxine challenge in experimental hepatic encephalopathy.

    abstract::Venlafaxine (VEN) pharmacokinetics and effects on the brain monoamine output were investigated in the context of experimental hepatic encephalopathy (HE). Systemic VEN (10 mg/kg; subcutaneous) was administered to chronic portacaval shunted (PCS) and sham-operated rats. Their neocortical extracellular levels of 5-HT, 5...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:

    authors: Wikell C,Bergqvist PB,Hjorth S,Apelqvist G,Björk H,Bengtsson F

    更新日期:1998-09-01 00:00:00

  • Rotigotine Transdermal Patch Does Not Make Parkinson Disease Patients Sleepy During Daytime.

    abstract:OBJECTIVES:To assess quantitatively the influence of rotigotine transdermal patch on daytime sleepiness, the most common adverse event by non-ergot dopamine agonists (DAs), in Parkinson disease (PD) patients. METHODS:An open-label study enrolled PD patients with unsatisfactory control of motor symptoms. Treatment with...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/WNF.0000000000000110

    authors: Ohta K,Osada T

    更新日期:2015-11-01 00:00:00

  • Poor tolerability of a transdermal nicotine treatment in Parkinson's disease.

    abstract::Studies assessing the effect of transdermal nicotine in Parkinson's disease (PD) have generated mixed results regarding its efficacy to treat motor and cognitive deficits. These studies generally reported good tolerability in nonsmoking PD patients. The authors report the tolerability data of an open trial with transd...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/00002826-200309000-00004

    authors: Lemay S,Blanchet P,Chouinard S,Masson H,Soland V,Bédard MA

    更新日期:2003-09-01 00:00:00

  • A review of the randomized controlled trials of tacrine in the treatment of Alzheimer's disease: methodologic considerations.

    abstract::This review examines the features of the 16 randomized controlled trials that have been published on the use of oral tacrine for treating probable Alzheimer's disease and explores the methodologic problems associated with these studies. Patient selection using the standard National Institute of Neurological and Commun...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章,评审

    doi:

    authors: Conway EL

    更新日期:1998-01-01 00:00:00

  • Palinopsia induced by topiramate and zonisamide in a patient with migraine.

    abstract::Palinopsia is an illusory visual phenomenon consisting in the persistence or recurrence of visual images after the exciting stimulus object has been removed. It has been reported in association with parietal and occipital lobe lesions, migraine auras, and related to the use of several drugs and illicit drugs. Here, we...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/WNF.0b013e3182849208

    authors: Sierra-Hidalgo F,de Pablo-Fernández E

    更新日期:2013-03-01 00:00:00

  • Effects of serotonergic and anticholinergic drugs in haloperidol-induced dystonia in Cebus monkeys.

    abstract::In rodents, serotonin (5-HT) antagonists counteract behavioral and biochemical effects of neuroleptic drugs. Therefore, we have studied the effect of different 5-HT drugs and one anticholinergic drug in acute dystonia in five cebus monkeys chronically treated with haloperidol. Acute dystonia induced by subcutaneous in...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/00002826-198602000-00010

    authors: Povlsen UJ,Noring U,Laursen AL,Korsgaard S,Gerlach J

    更新日期:1986-01-01 00:00:00

  • Naloxone or haloperidol but not yohimbine reverse apomorphine-induced respiratory depression.

    abstract::Intravenous injection of low doses of naloxone was found to reverse the respiratory depression induced by apomorphine in chloralose-anesthesized dogs. Similar results were obtained with haloperidol, whereas yohimbine remained ineffective. These data suggest that apomorphine depresses respiratory rate through a mechani...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/00002826-199210000-00009

    authors: Montastruc JL,Rascol O,Montastruc P

    更新日期:1992-10-01 00:00:00

  • First clinical evaluation of ganstigmine in patients with probable Alzheimer's disease.

    abstract::The objective of this study was to evaluate the safety, tolerability, maximum tolerated dose, pharmacokinetics, and pharmacodynamics of five fixed doses of ganstigmine (CHF 2819) in patients with probable Alzheimer's disease (AD). This randomized, double-blind, placebo-controlled trial evaluated five dose levels (5, 7...

    journal_title:Clinical neuropharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/00002826-200305000-00011

    authors: Jhee SS,Fabbri L,Piccinno A,Monici P,Moran S,Zarotsky V,Tan EY,Frackiewicz EJ,Shiovitz T

    更新日期:2003-05-01 00:00:00

  • Clinical pharmacology and mechanism of action of zonisamide.

    abstract::Antiepileptic drugs (AEDs) suppress seizures by selectively modifying the excitability of neurons and blocking seizure firing with minimal disturbance of nonepileptic activity. All AEDs have been shown to work by at least one of 3 main mechanisms of action: through modulation of voltage-gated ion channels, enhancement...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/wnf.0b013e3180413d7d

    authors: Biton V

    更新日期:2007-07-01 00:00:00

  • Clozapine-induced obsessive-compulsive syndromes improve in combination with aripiprazole.

    abstract::Patients with schizophrenia often experience comorbid obsessive-compulsive syndromes (OCSs). Within these patients, a significant subgroup developed secondary OCS during treatment with antiserotonergic, atypical antipsychotic agents such as clozapine. Although cognitive behavioral therapy and antiobsessive antidepress...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/WNF.0b013e31819cc8e6

    authors: Englisch S,Esslinger C,Inta D,Weinbrenner A,Peus V,Gutschalk A,Schirmbeck F,Zink M

    更新日期:2009-07-01 00:00:00

  • Calcitonin Gene-Related Peptide-Targeted Therapies for Migraine and Cluster Headache: A Review.

    abstract::Calcitonin gene-related peptide (CGRP) is a signaling neuropeptide released from activated trigeminal sensory afferents in headache and facial pain disorders. There are a handful of CGRP-targeted therapies currently in phase 3 studies for migraine acute treatment or prevention. Currently, 4 monoclonal antibodies targe...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/WNF.0000000000000227

    authors: Schuster NM,Rapoport AM

    更新日期:2017-07-01 00:00:00

  • One-Year Retention Study of Adjunctive Perampanel Treatment in Epilepsy Patients.

    abstract:OBJECTIVES:Perampanel is a recently introduced antiepileptic drug (AED) with a unique action mechanism of noncompetitive and selective α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid antagonist. Because of delayed approval of perampanel in most Asian countries, there is limited information on the clinical usefulne...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/WNF.0000000000000255

    authors: Kim DW,Oh J

    更新日期:2018-01-01 00:00:00

  • Levetiracetam is not effective for essential tremor.

    abstract:OBJECTIVE:To determine if levetiracetam is efficacious in the treatment of essential tremor. METHODS:Fifteen patients (3 women), aged 35 to 83 years, with essential tremor were studied in a double-blind, placebo-controlled crossover trial of levetiracetam. During the 2 treatment periods, levetiracetam or placebo was t...

    journal_title:Clinical neuropharmacology

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:10.1097/WNF.0b013E31807A32C6

    authors: Elble RJ,Lyons KE,Pahwa R

    更新日期:2007-11-01 00:00:00

  • Is history of depression a contraindication to treatment with tetrabenazine?

    abstract:OBJECTIVE:To determine whether a history of depression predisposes hyperkinetic patients treated with tetrabenazine (TBZ) to a recurrence or worsening of this symptom. METHODS:We retrospectively reviewed the charts of 518 patients treated with TBZ to determine the frequency of depression and other adverse events. Char...

    journal_title:Clinical neuropharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1097/01.WNF.0000228369.25593.35

    authors: Kenney C,Hunter C,Mejia N,Jankovic J

    更新日期:2006-09-01 00:00:00

  • Drug-induced psychosis in Parkinson disease: phenomenology and correlations among psychosis rating instruments.

    abstract:OBJECTIVES:To describe further the phenomenology of drug-induced psychosis (DIP) in patients with Parkinson disease (PD) and assess which items on two common psychosis rating instruments-the Brief Psychiatric Rating Scale (BPRS) and the Neuropsychiatric Inventory (NPI)-are the best measure of DIP by comparing them with...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章,随机对照试验

    doi:10.1097/01.wnf.0000180228.77802.32

    authors: Chou KL,Messing S,Oakes D,Feldman PD,Breier A,Friedman JH

    更新日期:2005-09-01 00:00:00

  • Therapeutic effects of arotinolol, a beta-adrenergic blocker, on tremor in MPTP-induced parkinsonian monkeys.

    abstract::The effect of arotinolol, a peripherally acting beta-adrenergic-blocking agent, on postural or kinetic tremor was studied in monkeys with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism. Male cynomolgus monkeys (Macaca fascicularis) were treated with three injections of MPTP hydrochloride (0.3...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/00002826-199210000-00005

    authors: Kuno S,Mizuta E,Nishida J,Takechi M

    更新日期:1992-10-01 00:00:00

  • Early Onset Schizophrenia Associated With Obsessive-Compulsive Disorder: Clinical Features and Correlates.

    abstract:OBJECTIVES:Obsessive-compulsive disorder (OCD) is notably a comorbid disorder in patients with schizophrenia. This study aimed to evaluate clinical features and correlates of early onset patients with schizophrenia with OCD. METHODS:In the present study, we included 10 patients with both schizophrenia and OCD and 19 p...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/WNF.0000000000000248

    authors: Baytunca B,Kalyoncu T,Ozel I,Erermiş S,Kayahan B,Öngur D

    更新日期:2017-11-01 00:00:00

  • Clinical experience of dose conversion ratios between 2 botulinum toxin products in the treatment of cervical dystonia.

    abstract:OBJECTIVES:The units of different botulinum toxin products are not identical, and the dose equivalence has been debated for several years. In the year 2000, our clinic changed the recommended botulinum toxin product from Botox to Dysport for the treatment of cervical dystonia. Based on published reports, where dose con...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/WNF.0b013e3182711fc0

    authors: Rystedt A,Nyholm D,Naver H

    更新日期:2012-11-01 00:00:00

  • Beneficial effect of fluoxetine in a case of sporadic hyperekplexia.

    abstract::We studied a 67-year-old woman with a sporadic form of hyperekplexia, who experienced 8-10 excessive startle responses to unexpected stimuli per month. Therapy with fluoxetine had a definite beneficial effect. This finding supports the hypothesis that serotonergic mechanisms play a role in this disorder. ...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/00002826-200005000-00006

    authors: Sechi G,Sotgiu S,Valenti MP,Pitzolu MG,Peterlongo P,Larizza L,Rosati G

    更新日期:2000-05-01 00:00:00

  • Color vision in Parkinson's disease: missing influence of amantadine sulphate.

    abstract::In recent studies, disorders of chromatic and achromatic vision in parkinsonian patients have been demonstrated; these could be partially restored after application of L-Dopa. In this study, the effect of a 3-day infusion therapy with amantadine sulphate on color vision was evaluated in 19 parkinsonian patients by use...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/00002826-199510000-00009

    authors: Büttner T,Kuhn W,Müller T,Patzold T,Przuntek H

    更新日期:1995-10-01 00:00:00

  • Metabolic and hormonal effects of dexfenfluramine on stress situations.

    abstract::Chronic treatment of rats with dexfenfluramine decreased the concentrations of circulating corticosterone, fatty acid, glycerol, and triacylglycerol after feeding a test load of fructose. It also decreased the rise in adrenalin in the blood of rats that were anaesthetized with urethane. These effects of dexfenfluramin...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:

    authors: Brindley DN

    更新日期:1988-01-01 00:00:00

  • Effectiveness of switching from aripiprazole to ziprasidone in patients with schizophrenia.

    abstract:OBJECTIVES:Aripiprazole and ziprasidone are 2 antipsychotic medications that are relatively devoid of the metabolic adverse effects associated with the second-generation antipsychotics. This study aimed to evaluate the effectiveness of switching to ziprasidone in patients who had insufficient response or intolerance to...

    journal_title:Clinical neuropharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1097/WNF.0b013e3181d52b85

    authors: Kim SW,Shin IS,Kim JM,Bae KY,Yang SJ,Yoon JS

    更新日期:2010-05-01 00:00:00

  • The emergence of devastating impulse control disorders during dopamine agonist therapy of the restless legs syndrome.

    abstract:INTRODUCTION:The Restless Legs Syndrome is a common sensorimotor disorder, typically amenable to treatment with dopamine agonist therapy. Dopamine agonists have been associated with emergent impulse control disorders (ICDs) when used in patients with Parkinson disease, and ICDs have now been reported in individuals wit...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/WNF.0b013e31820d6699

    authors: Dang D,Cunnington D,Swieca J

    更新日期:2011-03-01 00:00:00

  • Rhabdomyolysis associated with clozapine treatment in a patient with decreased calcium-dependent potassium permeability of cell membranes.

    abstract::A 21-year-old patient developed rhabdomyolysis during his nineteenth week of treatment with clozapine for drug-resistant schizophrenia. No risk factors for rhabdomyolysis were found, but the calcium-dependent potassium efflux, normally responsible for membrane hyperpolarization and muscle refractoriness, was severely ...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:

    authors: Koren W,Koren E,Nacasch N,Ehrenfeld M,Gur H

    更新日期:1998-07-01 00:00:00

  • Association of SNAP-25, SLC6A2, and LPHN3 with OROS methylphenidate treatment response in attention-deficit/hyperactivity disorder.

    abstract:OBJECTIVES:Our study aimed to identify the association of norepinephrine transporter gene (SLC6A2), synaptosomal-associated protein of the 25-kDa gene (SNAP-25), and latrophilin 3 gene (LPHN3) with osmotic-controlled release oral delivery system methylphenidate (OROS MPH) treatment response. METHODS:One hundred thirty...

    journal_title:Clinical neuropharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1097/WNF.0000000000000045

    authors: Song J,Kim SW,Hong HJ,Lee MG,Lee BW,Choi TK,Lee SH,Yook KH

    更新日期:2014-09-01 00:00:00

  • Cognitive improvement in clinical trials with nootropic drugs: when can it be expected and how to clarify its meaning.

    abstract::In order to have a correct evaluation of the activity of a nootropic drug, the criteria adopted for the choice of patients to be included in the clinical trials and the methods used to clarify the meaning of changes observed on cognitive tasks are reported. The results of a clinical trial with the nootropic oxiracetam...

    journal_title:Clinical neuropharmacology

    pub_type: 临床试验,杂志文章

    doi:

    authors: Gainotti G,Benedetti N,Caltagirone C,Nocentini U

    更新日期:1986-01-01 00:00:00

  • Clinical usefulness of apomorphine in movement disorders.

    abstract::Apomorphine, the first dopamine agonist to be synthesized, has received a renewed interest in the last few years. This compound acts powerfully on D1 and D2 dopamine receptors and has the most complete pharmacological profile of all clinically available dopamine agonists. When given subcutaneously, apomorphine consist...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/00002826-199406000-00004

    authors: Colosimo C,Merello M,Albanese A

    更新日期:1994-06-01 00:00:00

  • Amantadine sulfate infusion effect on N30 somatosensory evoked potentials in Parkinson's disease.

    abstract::The purpose of this study was to evaluate the effect of amantadine sulfate infusion on the N30 component of the median nerve short-latency somatosensory evoked potentials (SSEPs) in patients with Parkinson's disease (PD). Twenty patients with advanced PD and severe motor fluctuations received a 6-day course of amantad...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/00002826-200203000-00011

    authors: Bostantjopoulou S,Katsarou Z,Georgiadis G,Zafiriou D,Kazis A

    更新日期:2002-03-01 00:00:00